Patient Gateway

RSS Feed

University Hospital Puerta de Hierro Majadahonda Describes Findings in Obesity, Fitness and Wellness (Real-world evolution of first-line ALK-positive NSCLC management in Spain)

Targeted Drug ALK Inhibitors for NSCLC Market Size & CAGR 2033

Clinical Trial: Neoadjuvant Iruplinalkib and Bevacizumab in ALK-positive NSCLC: A Phase II Single-arm Trial

ALK-Positive Non-Small Cell Lung Cancer Market, Epidemiology, And 7MM Forecast To 2036 Market To Reach USD 3.37 Billion As Next-Generation ALK Inhibitors Drive Growth

ALK-Positive Non-Small Cell Lung Cancer Market, Epidemiology, and 7MM Forecast to 2036

Hong Kong Model Finds EGFR/ALK-First Testing More Cost-Efficient Than Upfront NGS in Metastatic NSCLC

Hong Kong Model Finds EGFR/ALK-First Testing More Cost-Efficient Than Upfront NGS in Metastatic NSCLC

Ensartinib Treatment for Rare Nonclassical ALK Fusion Lung Adenocarcinoma With Brain Metastasis

Efficacy and safety of adjuvant ensartinib in stage I ALK-positive NSCLC patients: a retrospective, multicenter study

Data on Obesity, Fitness and Wellness Discussed by Researchers at Army Medical University (Low-Concentration Enhancement Effect: Enabling Sensitive Detection of EML4-ALK Variants via Multiplex RT-MIRA)

Lung Cancer Was a Death Sentence. Now Drugs Are Saving Lives.